Replies to post #1508 on Opiant Pharmaceuticals Inc. (OPNT)

[MasterSalix]

Absurd that there isn’t more attention on this one…been riding for a long while, but even here at $32 it has a relatively low m/c considering the amount of cash (+$50M), revs increasing, profits increasing, trial results pending, and the fact that they just raised guidance even more…

Still has relatively low volume and there is still way more value even from these levels -

Ultimately, I think they are a prime buyout candidate from a much larger entity. Think once approval comes through things will move fast and furious - 22’ is setting up as an awesome year for this one - GL2U.